Why Lipocine (LPCN) Stock Is Surging in Morning Trading Today

NEW YORK (TheStreet) -- Shares of Lipocine  (LPCN) soared 50.4% to $7.85 in morning trading Wednesday after the pharmaceutical company announced positive results from its Phase 3 trial of its oral treatment LPCN 1021 for low testosterone in a study of oral androgen replacement, or SOAR.

The treatment met its primary efficacy endpoint in the trial as it restored testosterone levels to the normal range in 88% of male subjects with hypogonadism, a condition in which the body does not produce enough testosterone. The company reported no serious adverse events in relation to the drug.

Lipocine reiterated its expectation to file a New Drug Application with the FDA in the second half of 2015.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More than 1.7 million shares had changed hands as of 9:50 a.m., compared to the average volume of 56,477.

LPCN Chart LPCN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Stocks Slide on Renewed Trade War Concerns

Stocks Slide on Renewed Trade War Concerns

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know

China Trade War, Google, JD.com, Tesla, Brooks Koepka - 5 Things You Must Know